FDA Recalls GLP-1 Weight-Loss Injections Over Sterility Concerns: What Patients Need To Know
Certain compounded tirzepatide weight-loss injections were voluntarily recalled in the United States on Sept. 24, 2026, after the manufacturer, Apothecary Pharma LLC, could not…
DO
By Daniel Okafor · Regulatory Correspondent
Oct 21 09:02 ETSource: International Business Times, Singapore Edition
From the source
Read at ibtimes.sgFDA Recalls GLP-1 Weight-Loss Injections Over Sterility Concerns: What Patients Need To Know
Certain compounded tirzepatide weight-loss injections were voluntarily recalled in the United States on Sept. 24, 2026, after the manufacturer, Apothecary Pharma LLC, could not assure their sterility. The U.S. Food and Drug Administration (FDA) classified the recall as Class II on Oct. 10, meaning exposure could cause temporary or medically reversible health problems. The recall concerns specific
